Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We report a reliable fully automated procedure to produce a promising F-18 labeled sphingosine-1-phosphate receptor 1 (S1PR1) PET ligand, 3-((2-fluoro-4-(5-(4-(2-(fluoro-F)ethoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-3-yl)benzyl) (methyl)amino)propan-1-ol ([F]FZTA) on the GE TRACERlab FX2N module, using a one-pot two-step procedure following current Good Manufacturing Practices (cGMP). The MOM-protected precursor 1 was fluorinated with no-carrier-added [F]KF, catalyzed by Kryptofix 222 under heat, to afford the intermediate [F]2. After deprotecting the MOM-group on [F]2 under acidic condition, the reaction was quenched into a neutralized solution, which was then loaded on semi-preparative HPLC for purification. The collected product [F]FZTA was trapped on Sep-Pak C18 cartridge and formulated in 10 % ethanol/saline solution for quality control. The radiosynthesis of [F]FZTA was accomplished in approximately 60 min with radiochemical yield of 13.9 ± 2.9 %, radiochemical purity >91 %, and molar activity >147 GBq/μmol (n = 3, decay corrected to end of synthesis (EOS)). We successfully achieved three consecutive validation runs and the radiopharmaceutical products met all quality control criteria and specifications of the exploratory Investigational New Drug (IND) application for use of the PET radiotracer in human subjects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.apradiso.2025.112136 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
S1P/S1PR4 Promotes the Differentiation of CD8 tissue-resident memory T Cells Aggravating Bile Duct Injury in Biliary Atresia.
J Hepatol
September 2025
Department of Neonatal Surgery, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China. Electronic address:
Background And Aims: Biliary atresia (BA) is a severe neonatal cholangiopathy characterized by progressive inflammation and fibrosis. We aimed to systematically investigate BA pathology using integrated multi-omics.
Methods: Multi-omics integration of BA and control livers revealed sphingolipid dysregulation.
A Randomized Trial on the Combined Effect of Ponesimod and Propranolol on Heart Rate, Cardiac Safety, and Pharmacokinetics in Healthy Adults.
Clin Transl Sci
September 2025
Johnson & Johnson, Allschwil, Switzerland.
The objective of this phase 1 study was to evaluate the pharmacokinetics (PK), pharmacodynamics, and cardiac effect following administration of ponesimod (a selective sphingosine-1-phosphate receptor modulator) and propranolol in healthy adults. In treatment period (TP) 1, participants received ponesimod (2 mg). In TP2, if resting heart rate (HR) was ≥ 55 bpm, the ponesimod up-titration regimen was initiated.
View Article and Find Full Text PDFDiscovery and SAR study of highly selective and potent 1,2,4-oxadiazole-based S1PR1 agonists.
Eur J Med Chem
August 2025
School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, China. Electronic address:
Sphingosine-1-phosphate receptor 1 (S1PR1) is a validated therapeutic target for immune-mediated diseases such as multiple sclerosis and ulcerative colitis, owing to its critical role in regulating of lymphocyte migration. However, the clinical utility of current S1PR1 agonists is often limited by cardiovascular adverse effects, particularly dose-dependent bradycardia. Enhancing receptor subtype selectivity represents a promising strategy to mitigate these risks.
View Article and Find Full Text PDFFuture of inflammatory bowel disease treatment: A review of novel treatments beyond guidelines.
World J Methodol
December 2025
Department of Gastroenterology, Firat University, Elazig 23119, Türkiye.
Inflammatory bowel disease (IBD) is a chronic condition consisting of two main types: Crohn's disease and ulcerative colitis. Conventional treatments for these diseases include aminosalicylates, corticosteroids, immunomodulators, and biologics. However, these treatments have several drawbacks, including high costs for patients and numerous side effects.
View Article and Find Full Text PDFFingolimod as a Potential Cerebroprotectant Results From the Stroke Preclinical Assessment Network.
Stroke
September 2025
Department of Neurology, Yale University School of Medicine, New Haven, CT. (L.S.B.B., A.L.H., H.E.B., C.W.J., J.G., L.H.S.).
Background: Fingolimod is an immunomodulatory drug that has shown promising effects in stroke treatment, including improvements in neurofunctional recovery and a reduction in infarct size. Fingolimod modulates the sphingosine-1-phosphate receptors, which leads to the internalization of sphingosine-1-phosphate receptors on T and B lymphocytes, thereby preventing their egress from secondary lymphoid organs. Here, we report a secondary analysis from the Stroke Preclinical Assessment Network trial.
View Article and Find Full Text PDF